Michael Schwitter
Kantonsspital St. Gallen
16 Papers
47 Citations
Michael Schwitter is an academic researcher from Kantonsspital St. Gallen. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?
Richard Cathomas,Christian Rothermundt,Beata Bode,Bruno Fuchs,Roger von Moos,Michael Schwitter +5 more
TL;DR: This is the first report of activity achieved by the combination of the tyrosine kinase inhibitor sorafenib and the RANKL inhibitor denosumab in a patient with osteosarcoma and could serve as a hypothesis-generating approach for clinical trials in this patient population.
Dyspnoea and a lung mass in a young female 2 weeks after Caesarean delivery
TL;DR: A 28-yr-old female presented 2 weeks after an uneventful delivery by Caesarean section with progressive cough, dyspnoea and left-sided chest pain and a malignant process was diagnosed, and the surgeon proceeded to a left upper lobectomy and mediastinal lymphadenectomy.
12
Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
Michael Schwitter,Regulo Rodriguez,Tino Schneider,Thomas Kluckert,Martin Brutsche,Martin Früh +5 more
TL;DR: The case of a 64-year-old ex-smoker with metastatic poorly differentiated squamous cell carcinoma of the lung and an epidermal growth factor receptor (EGFR) mutation in exon 21 who achieved prolonged clinical benefit from treatment with an EGFR tyrosine kinase inhibitor (TKI) is reported.
Effect of an interprofessional small-group communication skills training incorporating critical incident approaches in an acute care and rehabilitation clinic specialized for spinal cord injury and disorder
Anke Scheel-Sailer,S. Eich,Luca Jelmoni,Patricia Lampart,Michael Schwitter,Diana Sigrist-Nix,Wolf Langewitz +6 more
TL;DR: During seven years of continuous training, independent patient ratings of satisfaction with professional communication have improved significantly, and inter-professional CST is feasible and well accepted by professionals from various professional groups.
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)
Andreas Müller,Arnoud J. Templeton,Stefanie Hayoz,Hanne Hawle,U Hasler-Strub,Michael Schwitter,B. Pestalozzi,O. Pagani,P Butzberger,Tobias Wehrhahn,Dieter Rauch,R. Inauen,Daniel C. Betticher,Khan Shah Zaman,Alexandre Bodmer,R. A. Popescu,Sacha I. Rothschild,J Schardt,Markus Borner,Andrea Fuhrer,Corinne Schär,Silke Gillessen,R. von Moos +22 more
TL;DR: Up to 20% of all BC patients treated with DN experienced HC in the q4w induction phase despite mandatory supplementation of VitD and Ca, considerably higher than the numbers reported in the registration trials of DN.
3